O
CMPX icon

OrbiMed’s Compass Therapeutics CMPX Stock Holding History

OrbiMed’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.3M Hold
15,219,994
– – 0.62% 47
2026
Q1 		$80.5M Hold
15,219,994
– – 1.6% 16
2025
Q4 		$81.7M Hold
15,219,994
– – 1.67% 19
2025
Q3 		$53.3M Hold
15,219,994
– – 1.25% 25
2025
Q2 		$39.6M Sell
15,219,994
-7,142,856
-32% -$14.7M 0.99% 28
2025
Q1 		$42.5M Hold
22,362,850
– – 1.01% 28
2024
Q4 		$32.4M Hold
22,362,850
– – 0.67% 41
2024
Q3 		$41.1M Hold
22,362,850
– – 0.75% 40
2024
Q2 		$22.4M Hold
22,362,850
– – 0.44% 58
2024
Q1 		$44.3M Hold
22,362,850
– – 0.81% 42
2023
Q4 		$34.9M Hold
22,362,850
– – 0.7% 51
2023
Q3 		$44.1M Hold
22,362,850
– – 0.94% 40
2023
Q2 		$71.1M Hold
22,362,850
– – 1.29% 29
2023
Q1 		$73.1M Hold
22,362,850
– – 1.44% 20
2022
Q4 		$112M Buy
22,362,850
+402,000
+2% +$1.6M 2.15% 14
2022
Q3 		$50.1M Hold
21,960,850
– – 0.93% 40
2022
Q2 		$58.2M Buy
21,960,850
+317,875
+1% +$690K 1.05% 33
2022
Q1 		$29.7M Hold
21,642,975
– – 0.48% 54
2021
Q4 		$68.6M Buy
+21,642,975
New +$71.8M 0.88% 39

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed's CMPX Position: Q2 2026 in Review

OrbiMed held its Compass Therapeutics (CMPX) position steady in Q2 2026 at 15,219,994 shares worth $33.3M. The position accounts for 0.62% of the portfolio, ranked #47.

OrbiMed first reported a position in CMPX in Q4 2021 and has held it in 19 quarters since. The position peaked at $112M in Q4 2022. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • OrbiMed held 15,219,994 shares of Compass Therapeutics worth $33.3M as of Q2 2026.
  • OrbiMed left its Compass Therapeutics share count unchanged in Q2 2026.
  • Compass Therapeutics made up 0.62% of OrbiMed's portfolio in Q2 2026, its #47 holding.
  • OrbiMed first reported a position in Compass Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • OrbiMed's Compass Therapeutics position peaked at $112M in Q4 2022.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.